Acteris, Inc. is a privately held development stage biotechnology company engaged in improving development and use of novel cancer immunotherapeutic products. It focuses on targeting cancer immunotherapies to specific tumors, patients, and therapeutic combinations to optimize patient outcomes. To achieve this, Acteris partners with pharmaceutical and biotechnology companies to improve the development and commercialization of their therapeutic candidates.
Founded on seminal discoveries at UCLA in the field of anti-PD1 therapy, Acteris is focused on applying these advances to help improve the development of immunotherapies by selecting therapeutic candidates and optimizing patient responses.
Acteris highlights the potential to apply the well-proven use of personalized medicine to the revolutionary field of cancer immunotherapy. By applying this platform to selection, development, and use of cancer immunotherapies, Acteris may substantially improve patient outcomes and further transform drug R&D in the emerging field of cancer immunotherapy.
Paul Tumeh, M.D.
Dr. Tumeh is a physician-scientist at UCLA Medical Center in Los Angeles, California. He is an NIH-funded investigator and the recipient of STOP Cancer Research Career Development Award, the priniciple investigator and mentor of a Howard Hughes Medical Institute (HHMI) Medical Research Fellows Program, and Kure It Investigator Award. His publications include Nature, New England Journal of Medicine, and Clinical Cancer Research. His lab is focused on identifying and investigating discrete cellular microenvironments within tumors that drive or inhibit to therapies that block the PD1/PDL1 axis and other cancer immunotherapies. His postdoctoral fellowships were under Wafik El-Deiry, MD, PhD, and Dr. Antoni Ribas, MD, PhD in tumor immunology. He graduated AOA from University of Southern California School of Medicine, completed his medical internship at the Hospital of the University of Pennsylvania, and trained under Noah Craft MD, PhD in dermatology at Harbor-UCLA Medical Center.
Toni Ribas, M.D. Ph.D.
Dr. Ribas is an award-winning physician-scientist specializing in malignant melanoma. He is a Professor in the Department of Medicine in Hematology and Oncology at the UCLA School of Medicine, the Director of the JCCC Tumor Immunology Program Area, a Member of the JCCC Signal Transduction and Therapeutics Program Area, General Clinical Research Center Advisory Board Member and faculty advisor to the UCLA Residency Program. He is also a member of the Cancer Research Institute clinical trials network, as well as the CRI/Stand Up to Cancer “Dream Team.” Ribas trained at the University of Barcelona in Spain, and has undergone postdoctoral training at the Sidney Kimmel Cancer Center in San Diego and at UCLA. He joined the UCLA Hematology-Oncology Fellowship program and has been a faculty member since July of 2001.
David Elashoff, Ph.D.
Dr. Elashoff is a Professor of Medicine and Biostatistics at UCLA and Director of the Department of Medicine Statistics Core. He serves as Leader for the Biostatistics, Study Design and Clinical Data Management Program (BSD-CDM) for the UCLA CTSI. His main areas of statistical research are in developing statistical methods for the analysis of high throughput genomic and proteomic data. He has extensive collaborative experience on a variety of basic science, clinical research and clinical trials projects, including those with members of the School of Dentistry, Department of Medicine, Jonsson Comprehensive Cancer Center (JCCC), School of Nursing, and investigators at their partner institutions. He specializes in the combination of genomics, proteomics, bioinformatics and clinical correlates. He is also a member of the Cancer Biomarkers Study Section of the NCI and is an author on over 150 publications. He holds a Ph.D. from Stanford University and completed his undergraduate training at MIT.
Mr. Johnson brings deep experience in the healthcare and diagnostics industries including licensing and transaction structuring, business and commercial case development, health economics and pricing. He was previously President of Diadexus in 2014 and with Novartis from 2009 to 2014 in a series of roles of increasing responsibility, most recently as director of Mergers and Acquisitions based in the company’s headquarters in Basel, Switzerland. Prior to his tenure in Switzerland, Mr. Johnson worked in Business Development and Licensing for Novartis Diagnostics where he oversaw multiple licensing deals and led the creation of a new transplantation diagnostics business. Mr. Johnson started his career in finance in the Global Healthcare Group at UBS Investment Bank. He holds a bachelor’s degree in Economics from Union College and a Masters of Business Administration from Columbia University.